Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127200661 | 12720066 | 1 | I | 20160830 | 20160907 | 20160907 | EXP | CN-VIIV HEALTHCARE LIMITED-CN2016GSK128992 | VIIV | QIN L, WANG F, ZOU B-W, DING Z-Y. CHEMOTHERAPY INDUCED FATAL HEPATITIS B VIRUS REACTIVATION IN A SMALL CELL LUNG CANCER PATIENT. MOLECULAR AND CLINICAL ONCOLOGY. 2016;5:382-384 | 56.00 | YR | M | Y | 0.00000 | 20160907 | MD | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127200661 | 12720066 | 1 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | WITH CARBOPLATIN FOR 3 CYCLES | 0 | |||||||||||
| 127200661 | 12720066 | 2 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | WITH CISPLATIN FOR 1 CYCLES | 0 | |||||||||||
| 127200661 | 12720066 | 3 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | WITH CISPLATIN FOR 2 CYCLES | 0 | |||||||||||
| 127200661 | 12720066 | 4 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | WITH ETOPOSIDE FOR 3 CYCLES, CYC | 0 | |||||||||||
| 127200661 | 12720066 | 5 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | 100 MG, QD | 21003 | 100 | MG | QD | ||||||||
| 127200661 | 12720066 | 6 | SS | CISPLATIN. | CISPLATIN | 1 | WITH ETOPOSIDE FOR 1 CYCLE, CYC | 0 | |||||||||||
| 127200661 | 12720066 | 7 | SS | CISPLATIN. | CISPLATIN | 1 | WITH ETOPOSIDE FOR 2 CYCLE, CYC | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127200661 | 12720066 | 1 | Chemotherapy |
| 127200661 | 12720066 | 4 | Chemotherapy |
| 127200661 | 12720066 | 5 | Hepatitis B |
| 127200661 | 12720066 | 6 | Chemotherapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127200661 | 12720066 | DE |
| 127200661 | 12720066 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127200661 | 12720066 | Alanine aminotransferase increased | |
| 127200661 | 12720066 | Aspartate aminotransferase increased | |
| 127200661 | 12720066 | Blood bilirubin increased | |
| 127200661 | 12720066 | Bone marrow failure | |
| 127200661 | 12720066 | Condition aggravated | |
| 127200661 | 12720066 | Drug resistance | |
| 127200661 | 12720066 | Haemoptysis | |
| 127200661 | 12720066 | Hepatic encephalopathy | |
| 127200661 | 12720066 | Hepatitis B | |
| 127200661 | 12720066 | Hepatitis B DNA increased | |
| 127200661 | 12720066 | Hepatitis fulminant | |
| 127200661 | 12720066 | Hepatorenal syndrome | |
| 127200661 | 12720066 | Hyperammonaemia | |
| 127200661 | 12720066 | Hypoalbuminaemia | |
| 127200661 | 12720066 | Neoplasm progression | |
| 127200661 | 12720066 | Pancreatitis acute | |
| 127200661 | 12720066 | Pathogen resistance | |
| 127200661 | 12720066 | Viral mutation identified |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127200661 | 12720066 | 1 | 201409 | 0 | ||
| 127200661 | 12720066 | 2 | 201409 | 0 | ||
| 127200661 | 12720066 | 3 | 201502 | 0 | ||
| 127200661 | 12720066 | 4 | 201409 | 0 | ||
| 127200661 | 12720066 | 5 | 201409 | 2015 | 0 | |
| 127200661 | 12720066 | 6 | 201409 | 0 | ||
| 127200661 | 12720066 | 7 | 201502 | 0 |